Last reviewed · How we verify
Neosporin
At a glance
| Generic name | Neosporin |
|---|---|
| Sponsor | Yale University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Topical Antibacterial Agents for Prevention of COVID-19 (PHASE1)
- Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection (PHASE4)
- A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain (PHASE1)
- Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of Care (NA)
- Trial to Test if Antibiotic Ointments & Cream Will Sting After Application on a Minor Wound After Tape Stripping Injury (NA)
- Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment (NA)
- Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage (PHASE3)
- Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neosporin CI brief — competitive landscape report
- Neosporin updates RSS · CI watch RSS
- Yale University portfolio CI